鄧賢明DENG Xianming, Ph.D.
教授，博士生導師
化學生物學和藥物化學（Chemical Biology and Medicinal Chemistry Group）
課題組組長
2001年，廈門大學化學系化學專業，獲理學學士學位；
2006年，中科院上海有機化學研究所有機化學專業，獲理學博士學位；
2006年至2011年，哈佛醫學院Dana-Farber癌症研究所,博士後研究；
2011年10月起，為廈門大學生命科學學院“閩江學者”特聘教授，微生物藥物課題組學科帶頭人，入選中組部“青年千人”計畫。
2001，B.Sc., Xiamen University;
2006, Ph.D., Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences.
2006-2011, Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School.
2011.10-, Principal Investigator of Chemical Biology and Medicinal Chemistry Group, School of Life Sciences, Xiamen University.
主要研究領域（Research Area）
化學生物學和藥物化學。在化學生物學方面，我們集中於設計併合成新穎的針對蛋白激酶（Protein Kinase）和表觀遺傳蛋白（Epigenetic Enzyme）的小分子抑制劑，並運用這些功能小分子為工具，發現和解決信號傳導通路、神經生物學和癌症中的新問題。在藥物化學方面，以化學生物學研究成果為基礎，結合傳統的藥物化學手段（構效關係研究、藥代動力學和毒理學研究）進一步最佳化小分子工具化合物，以期發展針對癌症等相關疾病的“靶向治療”藥物。
Our research is focused on two major areas: chemical biology and medicinal chemistry. At the interface of chemistry and biology, we use organic synthesis to create new chemical tools for studying biological problems in human health and disease. These functional small-molecule tools are applied to control and elucidate cellular signal transduction in cancer, stem cell, and neural diseases. Second, we pursue established medicinal chemistry approaches including structure activity relationship (SAR) study and pharmacokinetics modification to optimize pre-clinical drug candidates. We're working to address the following general questions: a) How can we develop small-molecule modulators with selectivity towards desired targets such as protein kinases and epigenetic enzymes? b) How can we use discovered-small-molecule tools to dissect the molecular signaling pathways? c) How can we develop the 'lead' of targeted-drug from the tool compound?
